Hematopoietic stem cell transplantation (HSCT) is a widely accepted treatment for mainly hematopoietic disorders. Recent advances in transplantation techniques have increased the number of long-time survivors with chronic kidney disease (CKD). The presence of CKD affects outcomes and is associated with high mortality rates. Therefore, physicians treating transplant survivors should consider renal complications and optimize management of patients with CKD after HSCT. The pathology of CKD after HSCT is affected by many factors, and the causes of renal thrombotic microangiopathy (TMA) are diverse and complicated. We have treated patients who underwent allogeneic HSCT and developed latestage renal TMA possibly associated with graft-versus-host disease (GVHD). Administration of immunosuppressive drugs, such as calcineurin inhibitors, is typically reduced in patients with TMA.
Introduction
An increasing number of patients are undergoing hematopoietic stem cell transplantation (HSCT) to treat hematopoietic disorders such as leukemia and malignant lymphoma. Worldwide, more than 60,000 patients undergo HSCT annually 1 . In Japan, more than 5,000 patients (allogeneic: 3,500 and autologous: 1,500) a year undergo HSCT, and more than 70,000 patients have been treated with the technique during the past 20 years 2 . Cases of long-term survival are increasing with improvements in transplantation techniques; however, renal disorders that complicate the late stages after transplantation often progress to end-stage renal failure, which may lead to renal replacement therapy 3, 4 . Furthermore, renal complications increase morbidity and mortality rates 5 .
Medical professionals involved in transplantation medicine, including hematologists and nephrologists, should understand the pathology of renal disorders associated with HSCT, including the relevant treatment perspectives. However, the pathology of renal complications after HSCT is complicated, so clarifying the disease characteristics and establishing appropriate therapeutic methods are important yet difficult tasks.
We recently reported that renal thrombotic microangiopathy (TMA) is associated with chronic graft-versushost disease (GVHD) 6 8 . Transplant-associated TMA (TA-TMA) is generally diagnosed on the basis of laboratory findings such as hemolytic anemia, thrombocytopenia, and elevated lactate dehydrogenase level, because it is difficult to obtain tissue specimens from patients with severe physical conditions. In contrast, renal TMA refers to pathological TMA in the kidney, with or without sys-temic symptoms 9 . Characteristic morphological findings in renal TMA include fibrin thrombi within glomeruli and mesangiolysis and/or thrombosis involving arterioles or interlobular arteries, in conjunction with characteristic intimal swelling in vessels and occlusion of capillary loops 7, 9 . We have treated patients with renal TMA in which GVHD may have been involved in the pathogenesis. Renal GVHD has not been defined, although nephrotic syndrome is a well-known renal manifestation in chronic GVHD. In addition, the association between renal TMA and renal GVHD is controversial. In this article, we describe renal complications after HSCT, particularly the association between renal TMA and renal GVHD, and review the literature and our own research.
Review of Previous Literature

Renal Complications after HSCT
In the early stage after transplantation, the incidence of acute kidney injury (AKI) caused by renal complications associated with HSCT is high, and the incidence rate of AKI is higher after allogeneic HSCT than after autologous HSCT 10, 11 . The causes of AKI are believed to be severe infection, nephrotoxic drugs, acute GVHD, and systemic TMA in the presence of schistocytes. In contrast, during the late stage after transplantation, renal function gradually deteriorates for various reasons and ultimately progresses to end-stage renal failure 3 . The causes of chronic kidney disease (CKD) are repeated AKI attributable to various causes, long-term use of calcineurin inhibitors (CNIs) for GVHD prophylaxis and treatment, radiation nephropathy, nephrotic syndrome caused by GVHD, and renal TMA with or without systemic symptoms 4,12 . In general, health-related quality of life is substantially lower for people with CKD than for the general population. CKD is associated with cardiovascular risks and increased incidences of several cancers 13, 14 . Similarly, post-HSCT patients with CKD have a lower overall survival rate than those without CKD 15 . Previous studies of CKD after HSCT suggest that the pathology of renal disorders associated with transplantation is complicated and multifactorial. Careful monitoring of renal function, including albuminuria, is required for long-term survivors 16, 17 .
Renal Complications Associated with GVHD
Among the renal complications associated with GVHD, nephrotic syndrome is well known but rare 18, 19 . Most kidney biopsy images show membranous nephropathy with subepithelial deposits. Therefore, antigen-antibody complexes due to GVHD may be present. In addition, renal histopathological findings may include minimal change disease, focal segmental glomerulosclerosis, and IgA nephropathy 20, 21 . Increased production of tumor necrosis factor-alfa TNF-α and interferon-gamma IFN-γ by donor T cells was associated with development of nephrotic syndrome 22 . Disease activity increased after a dose reduction in immunosuppressive drugs, and increased drug administration improved proteinuria, which suggests that the symptoms were caused by GVHD. In contrast, an examination of autopsy cases by Kusumi et al. suggested that peritubular capillaritis (PTC-itis) and tubulitis may be GVHD-related lesions 23 . We also believe these findings to be related to renal GVHD. Kusumi et al. further speculated that the Banff classification for kidney transplantation may be a useful tool to assess renal pathology after allogeneic HSCT. The precise mechanism underlying kidney injury and GVHD is unclear, although the kidney is believed to be a target organ of GVHD.
Vascular Injury Mediated by GVHD
GVHD is an immune-mediated disorder believed to be driven by allospecific lymphocytes, as it does not occur after autologous HSCT. GVHD develops when donor- HSCT, suggesting an association of endothelial injury, acute GVHD, and subsequent development of TMA 26 28 .
Increasing evidence indicates that endothelial injuries mediated by GVHD are present. In the early stages after HSCT, severe endothelial injuries, such as TA-TMA, veno-occlusive disease of the liver, diffuse alveolar hemorrhage, engraftment syndrome, and capillary leak syndrome, all share features with acute GVHD 29 . In late stages, persistent endothelial injury associated with chronic GVHD leads to microvascular rarefaction, loss of microvessels, and, ultimately, to organ fibrosis. It is unclear whether the main contributor mediating endothelial cell injury is the T cell, another cell type, or another mechanism 28 . Furthermore, late cardiovascular accidents are more likely to occur in patients treated with allogeneic HSCT than in those treated with autologous HSCT, which suggests that an immunological mechanism is in- The causes of renal TMA are diverse. In general, TMA is believed to be caused by use of CNIs for GVHD prophylaxis, viral infection, and total body irradiation.
Therefore, administration of immunosuppressive drugs is commonly reduced or stopped. However, while this is common, we consider that renal TMA after allogeneic HSCT might result from GVHD and that administration of immunosuppressive drugs should thus be increased.
Authors' Findings
Renal TMA after Allogeneic HSCT: Involvement of
Chronic GVHD
We reported a case of progressive renal insufficiency accompanied by proteinuria 2 years after umbilical cord blood transplantation for refractory myelodysplastic syndrome 6 . A kidney biopsy showed severe endothelial cell injury of microvessels. Renal TMA was diagnosed, even though there were no clinical symptoms of TMA, except for hypertension ( Fig. 1) 6 . We initially thought that kidney injury was caused by use of CNI for GVHD prophylaxis. However, renal function deteriorated when CNI was gradually reduced and stopped. The patient ultimately required dialysis.
We were unsure of the cause of renal impairment. Further pathological analysis showed that, in addition to vascular endothelial cell injury, there was glomerulitis, PTC-itis, tubulitis, and C4d deposition in the glomerular basement membrane and patchy PTCs. These findings were similar to those seen in images of chronic antibodymediated rejection in kidney transplantation. These find- Renal TMA is not a common manifestation of renal GVHD. We attempted to use animal experiments to ex- amine the relationship between renal TMA and GVHD.
We created a GVHD model of Lewis rats transplanted with Dark Agouti (DA) rat bone marrow 34 . Two to four weeks after transplantation, symptoms characteristic of severe GVHD were observed in skin, liver, and gastrointestinal tract. Simultaneously, PTC-itis, tubulitis, and glomerulitis accompanied by infiltration of donor T lymphocytes were confirmed in the kidneys, which strongly suggests acute renal GVHD. Another study using a murine model of acute GVHD in several tissues, including kidneys with capillaritis, endothelialitis, and tubulitis, reported findings suggesting renal GVHD 35 . However, these models did not yield clear evidence of severe endothelial cell injury in human studies. Therefore, it is necessary to further examine renal manifestation in the late stage of our model or to create and investigate another model of chronic GVHD.
If the cause of renal TMA is GVHD, kidney function might improve after resuming or increasing administration of immunosuppressive drugs. When we resumed or increased the dosage of prednisolone in three of four patients with renal TMA and C4d deposition diagnosed with renal GVHD, renal insufficiency improved (Fig. 2) 8 .
This indicates that circulating antibodies to recipient endothelial cells are present and suggests that renal TMA can cause renal GVHD.
Future Perspectives
It has been common to reduce or stop immunosuppressive drugs when renal TMA develops after allogeneic HSCT, because CNI and infectious diseases were believed to be causes of TMA. If, as suggested here, the cause of renal TMA is renal GVHD, conventional treatments would not be appropriate and it would be necessary to increase administration of immunosuppressive drugs.
Evidence is increasing for the hypothesis that GVHD has a role in the development of renal TMA after allogeneic HSCT, but its pathology and treatment have not been clarified (Fig. 3) . We will continue to identify clinicopathological features and specific biomarkers of renal TMA involved in GVHD by examining more cases and using animal experiment models. We hope to contribute to further characterizing the disease and determining its treatment.
